IL165531A0 - GLP-1 and methods for treating diabetes - Google Patents
GLP-1 and methods for treating diabetesInfo
- Publication number
- IL165531A0 IL165531A0 IL16553104A IL16553104A IL165531A0 IL 165531 A0 IL165531 A0 IL 165531A0 IL 16553104 A IL16553104 A IL 16553104A IL 16553104 A IL16553104 A IL 16553104A IL 165531 A0 IL165531 A0 IL 165531A0
- Authority
- IL
- Israel
- Prior art keywords
- glp
- treating diabetes
- drug
- mammal
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The present invention relates to use of GLP-1 or a related molecule having GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a "drug holiday". Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagon like peptide (GLP-1) or a related molecule having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39391702P | 2002-07-04 | 2002-07-04 | |
US46561303P | 2003-04-24 | 2003-04-24 | |
PCT/DK2003/000463 WO2004005342A1 (en) | 2002-07-04 | 2003-07-02 | Glp-1 and methods for treating diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
IL165531A0 true IL165531A0 (en) | 2006-01-15 |
IL165531A IL165531A (en) | 2011-01-31 |
Family
ID=30118392
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL165531A IL165531A (en) | 2002-07-04 | 2004-12-02 | Glp-1, compositions comprising it and uses thereof |
IL208184A IL208184A (en) | 2002-07-04 | 2010-09-16 | Use of glp-1 agonist for the manufacture of a medicament for preventing or treating of diabetes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL208184A IL208184A (en) | 2002-07-04 | 2010-09-16 | Use of glp-1 agonist for the manufacture of a medicament for preventing or treating of diabetes |
Country Status (13)
Country | Link |
---|---|
US (3) | US20060057137A1 (en) |
EP (2) | EP2028192A1 (en) |
JP (2) | JP5685355B2 (en) |
AT (1) | ATE432289T1 (en) |
AU (3) | AU2003243929B2 (en) |
CA (1) | CA2490564A1 (en) |
DE (1) | DE60327771D1 (en) |
DK (1) | DK1525219T3 (en) |
ES (1) | ES2327328T3 (en) |
HK (1) | HK1075456A1 (en) |
IL (2) | IL165531A (en) |
MX (1) | MXPA04012497A (en) |
WO (1) | WO2004005342A1 (en) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
DE60335608D1 (en) * | 2002-02-27 | 2011-02-17 | Pharmain Corp | COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
AU2003283216A1 (en) * | 2002-12-03 | 2004-06-23 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
EP1688148A1 (en) * | 2002-12-03 | 2006-08-09 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
WO2006037811A2 (en) | 2004-10-07 | 2006-04-13 | Novo Nordisk A/S | Protracted exendin-4 compounds |
EP1799710A2 (en) * | 2004-10-07 | 2007-06-27 | Novo Nordisk A/S | Protracted glp-1 compounds |
US20060099282A1 (en) * | 2004-11-10 | 2006-05-11 | Kazuoki Ishihara | Product of coromandel and method for its use |
JP2008542301A (en) | 2005-05-26 | 2008-11-27 | メタバシス・セラピューティクス・インコーポレイテッド | Thyroid hormone-like drug for the treatment of fatty liver disease |
WO2007051987A1 (en) * | 2005-11-01 | 2007-05-10 | Activotec Spp Limited | Insulinotropic compounds and uses thereof |
KR101872061B1 (en) | 2005-12-19 | 2018-06-27 | 파마인 코포레이션 | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
DE102006031962A1 (en) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidated insulin glargine |
DE102006031955A1 (en) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Process for the preparation of dibasic B chain end insulin analogs |
US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
DE102008003568A1 (en) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | New insulin analogs useful for treating diabetes |
HUE030537T2 (en) | 2008-01-09 | 2017-05-29 | Sanofi Aventis Deutschland | Novel insulin derivatives having an extremely delayed time-action profile |
DE102008025007A1 (en) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes and for cartilage regeneration |
DE102008025008A1 (en) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes |
DE102008003566A1 (en) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | New insulin analogs useful for treating diabetes |
US20090176892A1 (en) | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
AU2009203810B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
DE102009038210A1 (en) | 2009-08-20 | 2011-03-03 | Sanofi-Aventis Deutschland Gmbh | Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist |
DE102008053048A1 (en) | 2008-10-24 | 2010-04-29 | Sanofi-Aventis Deutschland Gmbh | Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist |
DE102008051834A1 (en) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist |
SI2349324T1 (en) | 2008-10-17 | 2018-01-31 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
AR078973A1 (en) | 2009-11-13 | 2011-12-14 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION THAT INCLUDES AN GLP-1 AND METIONINE AGONIST |
US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
KR101836070B1 (en) * | 2009-11-13 | 2018-03-09 | 사노피-아벤티스 도이칠란트 게엠베하 | Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine |
AU2009238272B2 (en) * | 2009-11-13 | 2014-05-08 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
DE102010011919A1 (en) | 2010-03-18 | 2011-09-22 | Sanofi-Aventis Deutschland Gmbh | Liquid composition, useful for treating e.g. type II diabetes mellitus, and/or obesity, comprises a glucagon-like peptide-1 agonist and/or its salt e.g. exendin-4, optionally an adjuvant and methionine |
EP2563808B1 (en) | 2010-04-27 | 2016-12-07 | Zealand Pharma A/S | Peptide conjugates of glp-1 receptor agonists and gastrin and their use |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
SI2611458T1 (en) | 2010-08-30 | 2017-01-31 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
SI2651398T1 (en) | 2010-12-16 | 2018-04-30 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
MX370264B (en) | 2011-08-29 | 2019-12-09 | Sanofi Aventis Deutschland | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients. |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
WO2013050378A1 (en) | 2011-10-04 | 2013-04-11 | Sanofi-Aventis Deutschland Gmbh | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract |
SI2763690T1 (en) | 2011-10-04 | 2016-03-31 | Sanofi-Aventis Deutschland Gmbh | Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system |
WO2013064669A1 (en) | 2011-11-03 | 2013-05-10 | Zealand Pharma A/S | Glp-1 receptor agonist peptide gastrin conjugates |
US20130143800A1 (en) * | 2011-11-07 | 2013-06-06 | Research Development Foundation | Combination therapies to treat diabetes |
ES2690553T3 (en) | 2012-03-22 | 2018-11-21 | Novo Nordisk A/S | GLP-1 peptide compositions and preparation of these |
DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
WO2013162718A1 (en) * | 2012-04-24 | 2013-10-31 | Albert Einstein College Of Medicine Of Yeshiva University | Insulin secretion stimulated by humanin and analogs thereof |
US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
ES2620111T3 (en) | 2012-07-23 | 2017-06-27 | Zealand Pharma A/S | Glucagon analogues |
TWI608013B (en) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | Glucagon analogues |
UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
HUE038748T2 (en) | 2012-12-21 | 2018-11-28 | Sanofi Sa | Exendin-4 derivatives as dual glp1/gip- or trigonal glp1/gip/glucagon agonists |
TWI780236B (en) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
CA2907848A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
PT2991671T (en) | 2013-05-02 | 2018-11-05 | Novo Nordisk As | Oral dosing of glp-1 compounds |
MA38472B1 (en) | 2013-05-28 | 2018-09-28 | Takeda Pharmaceuticals Co | Peptide compound |
TWI666220B (en) | 2013-10-17 | 2019-07-21 | 丹麥商西蘭製藥公司 | Acylated glucagon analogues |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
MX369770B (en) | 2013-11-06 | 2019-11-21 | Zealand Pharma As | Glucagon-glp-1-gip triple agonist compounds. |
KR102310389B1 (en) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | Gip-glp-1 dual agonist compounds and methods |
TW201609799A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/GIP receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609796A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Non-acylated EXENDIN-4 peptide analogues |
AU2015205621A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
JP6735674B2 (en) | 2014-01-09 | 2020-08-05 | サノフイSanofi | Stabilized pharmaceutical formulation of insulin aspart |
RU2016132342A (en) | 2014-01-09 | 2018-02-14 | Санофи | STABILIZED PHARMACEUTICAL COMPOSITIONS BASED ON INSULIN ANALOGUES AND / OR INSULIN DERIVATIVES |
TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
HUE062573T2 (en) | 2014-12-12 | 2023-11-28 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
CN107636010B (en) | 2015-04-16 | 2021-10-01 | 西兰制药公司 | Acylated glucagon analogues |
AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
WO2017178829A1 (en) * | 2016-04-15 | 2017-10-19 | Imperial Innovations Limited | Peptide analogues |
CN109477094B (en) | 2016-05-24 | 2022-04-26 | 武田药品工业株式会社 | Peptide compounds |
EP3512523A4 (en) * | 2016-09-16 | 2020-05-06 | Viking Therapeutics, Inc. | Method of reducing thyroid-associated side effects |
BR112019010249A2 (en) | 2016-11-21 | 2019-09-10 | Viking Therapeutics Inc | glycogen storage disease treatment method |
BR112019010624A2 (en) | 2016-12-09 | 2019-10-22 | Zealand Pharma As | double acylated glp-1 / glp-2 agonists and composition |
EP3351262A1 (en) * | 2016-12-30 | 2018-07-25 | Istanbul Universitesi Rektorlugu | Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto |
EA201992703A1 (en) | 2017-06-05 | 2020-04-15 | Вайкинг Терапьютикс, Инк. | COMPOSITIONS FOR TREATING FIBROSIS |
WO2019149880A1 (en) | 2018-02-02 | 2019-08-08 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
US11787828B2 (en) | 2018-03-22 | 2023-10-17 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
EP3774838B1 (en) | 2018-04-10 | 2022-08-10 | Sanofi-Aventis Deutschland GmbH | Lixisenatide synthesis with capping |
BR112020020652A2 (en) | 2018-04-10 | 2021-03-02 | Sanofi-Aventis Deutschland Gmbh | method for cleaving peptides bound to the solid phase from the solid phase |
MX2021004875A (en) | 2018-10-30 | 2021-08-11 | Jianning Liu | Glp-1 polypeptide having glp-1 receptor agonist activity and uses thereof. |
EP4090351A4 (en) * | 2020-01-16 | 2023-09-13 | Shanghai Benemae Pharmaceutical Corporation | Dosing regimen of glp-1 |
AU2021324066A1 (en) * | 2020-08-12 | 2023-03-30 | Txp Pharma Ag | Exendin-4 peptide analogues |
WO2024040356A1 (en) * | 2022-08-25 | 2024-02-29 | The University Of British Columbia | Mucoadhesive pharmaceutical dosage form for unidirectional release of peptide therapeutic particles |
CN116730902B (en) * | 2023-08-07 | 2023-11-21 | 杭州湃肽生化科技有限公司 | Method for synthesizing liraglutide |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
EP0512042B1 (en) | 1990-01-24 | 1998-04-08 | BUCKLEY, Douglas I. | Glp-1 analogs useful for diabetes treatment |
DK36392D0 (en) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | USE OF CHEMICAL COMPOUND |
DK39892D0 (en) | 1992-03-25 | 1992-03-25 | Bernard Thorens | PEPTIDE |
US5846747A (en) | 1992-03-25 | 1998-12-08 | Novo Nordisk A/S | Method for detecting glucagon-like peptide-1 antagonists and agonists |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5523549A (en) | 1994-05-25 | 1996-06-04 | Ceramic Powders, Inc. | Ferrite compositions for use in a microwave oven |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US6110703A (en) | 1996-07-05 | 2000-08-29 | Novo Nordisk A/S | Method for the production of polypeptides |
DE69739172D1 (en) | 1996-08-08 | 2009-01-29 | Amylin Pharmaceuticals Inc | REGULATION OF GASTROINTESTINAL MOBILITY |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
CZ300837B6 (en) * | 1996-08-30 | 2009-08-26 | Novo Nordisk A/S | GLP-1 (7-37) derivatives or analogs thereof, pharmaceutical composition in which the derivatives are comprised as well as their use |
US6384016B1 (en) | 1998-03-13 | 2002-05-07 | Novo Nordisk A/S | Stabilized aqueous peptide solutions |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
UA65549C2 (en) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
ES2425559T5 (en) | 1997-01-07 | 2018-02-02 | Amylin Pharmaceuticals, Llc | Pharmaceutical compositions comprising exendins and their agonists |
US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
AU749914B2 (en) | 1997-08-08 | 2002-07-04 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
JP2001523688A (en) | 1997-11-14 | 2001-11-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | New exendin agonist compounds |
BR9815670A (en) | 1997-11-14 | 2000-10-17 | Amylin Pharmaceuticals Inc | Exendin agonist compounds |
CA2312190A1 (en) * | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | Glp-1 formulations |
WO1999043708A1 (en) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
WO2000020592A1 (en) | 1998-10-07 | 2000-04-13 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
US6271241B1 (en) | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
WO2000069911A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
US6344180B1 (en) * | 1999-06-15 | 2002-02-05 | Bionebraska, Inc. | GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
-
2003
- 2003-07-02 DE DE60327771T patent/DE60327771D1/en not_active Expired - Lifetime
- 2003-07-02 ES ES03762471T patent/ES2327328T3/en not_active Expired - Lifetime
- 2003-07-02 US US10/517,563 patent/US20060057137A1/en not_active Abandoned
- 2003-07-02 AU AU2003243929A patent/AU2003243929B2/en not_active Ceased
- 2003-07-02 AT AT03762471T patent/ATE432289T1/en not_active IP Right Cessation
- 2003-07-02 EP EP08016668A patent/EP2028192A1/en not_active Withdrawn
- 2003-07-02 WO PCT/DK2003/000463 patent/WO2004005342A1/en active Application Filing
- 2003-07-02 EP EP03762471A patent/EP1525219B1/en not_active Revoked
- 2003-07-02 MX MXPA04012497A patent/MXPA04012497A/en active IP Right Grant
- 2003-07-02 CA CA002490564A patent/CA2490564A1/en not_active Abandoned
- 2003-07-02 DK DK03762471T patent/DK1525219T3/en active
- 2003-07-02 JP JP2004518465A patent/JP5685355B2/en not_active Expired - Fee Related
-
2004
- 2004-12-02 IL IL165531A patent/IL165531A/en unknown
-
2005
- 2005-07-22 HK HK05106202.6A patent/HK1075456A1/en not_active IP Right Cessation
-
2008
- 2008-11-24 US US12/277,148 patent/US20090088369A1/en not_active Abandoned
-
2009
- 2009-06-15 AU AU2009202390A patent/AU2009202390B8/en not_active Ceased
-
2010
- 2010-09-16 IL IL208184A patent/IL208184A/en active IP Right Grant
- 2010-12-15 AU AU2010257216A patent/AU2010257216B2/en not_active Ceased
-
2012
- 2012-12-19 JP JP2012276583A patent/JP5758870B2/en not_active Expired - Fee Related
-
2014
- 2014-02-10 US US14/177,132 patent/US20140187483A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL208184A0 (en) | 2010-12-30 |
JP2013126981A (en) | 2013-06-27 |
AU2010257216A1 (en) | 2011-01-13 |
AU2009202390B8 (en) | 2010-11-11 |
EP1525219A1 (en) | 2005-04-27 |
DK1525219T3 (en) | 2009-09-07 |
DE60327771D1 (en) | 2009-07-09 |
HK1075456A1 (en) | 2005-12-16 |
CA2490564A1 (en) | 2004-01-15 |
IL208184A (en) | 2014-12-31 |
ATE432289T1 (en) | 2009-06-15 |
AU2010257216B2 (en) | 2012-09-27 |
AU2009202390A1 (en) | 2009-07-09 |
JP2006515267A (en) | 2006-05-25 |
US20090088369A1 (en) | 2009-04-02 |
EP1525219B1 (en) | 2009-05-27 |
WO2004005342A1 (en) | 2004-01-15 |
US20140187483A1 (en) | 2014-07-03 |
EP2028192A1 (en) | 2009-02-25 |
AU2009202390B2 (en) | 2010-10-07 |
AU2003243929B2 (en) | 2009-06-04 |
JP5685355B2 (en) | 2015-03-18 |
AU2003243929A1 (en) | 2004-01-23 |
IL165531A (en) | 2011-01-31 |
JP5758870B2 (en) | 2015-08-05 |
US20060057137A1 (en) | 2006-03-16 |
ES2327328T3 (en) | 2009-10-28 |
MXPA04012497A (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1075456A1 (en) | Glp-1 and methods for treating diabetes glp-1(1) | |
CY1118849T1 (en) | Combination therapy for the therapeutic treatment of Protein Deficiency Disorders | |
KR930702022A (en) | Treatment or prevention of type 1 diabetes by oral administration of insulin | |
ATE481970T1 (en) | COMPOSITIONS CONTAINING CAPSAICIN OR CAPSAICIN ANALOGUES AND AN AESTHETIC | |
BRPI0207700B8 (en) | mixture of monodisperse conjugates, pharmaceutical composition, and, use of a substantially monodisperse mixture of an insulin polypeptide-oligomer conjugate | |
NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
EP1514105A4 (en) | Methods of modulating tubulin deacetylase activity | |
WO2005058233A3 (en) | Methods for treatment of acute pancreatitis | |
DK1201246T3 (en) | Use of thrombopoietin as a drug for the treatment and prevention of thrombocytopenia | |
HK1034446A1 (en) | Therapeutic agents. | |
SE9702401D0 (en) | Pharmaceutical use | |
HK1061661A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
UA32457C2 (en) | Drug (variants) and methods for exposure to drug | |
WO2002064214A3 (en) | Anti cancer combination of substituted pyrroles and paclitaxel | |
BR0307022A (en) | Method of treating a patient who needs analgesia | |
NO20042100L (en) | Method for administering a thymosinal alpha 1 peptide | |
MXPA01012936A (en) | Pharmaceutical composition containing sibutramine and orlistat. | |
IT1293583B1 (en) | Treating demential syndromes comprising administration of gammahydroxybutyric acid | |
CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
SE0200598D0 (en) | Pharmaceutical composition and method of treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and / or ischemic consequences | |
DE60120371D1 (en) | USING GROWTH HORMONE IN LESS BOXES | |
NO20022187L (en) | Method of treating and preventing neurodegenerative disorders | |
MD1610G2 (en) | Method of the recidivating chronic aphthous stomatitis treatment | |
RU96115219A (en) | METHOD FOR TREATING PATIENTS WITH SUGAR DIABETES | |
MD1780G2 (en) | Method of treatment of patients with hepatic cirrhosis |